Antiretroviral medication considerations for individuals coinfected with HIV and hepatitis C virus.
There is great need to treat HIV/hepatitis C virus (HCV)-coinfected individuals with both antiretroviral and anti-HCV pharmacotherapy. However, treatment for HIV may lead to hepatotoxicity, and there are potential interactions and synergistic effects between antiretrovirals and anti-HCV medications. The ideal antiretroviral therapy options for coinfected patients, in the setting of anti-HCV treatment, are unclear and present important challenges to clinicians. We review the current data on the use of antiretrovirals in HIV/HCV-coinfected patients and offer evidence-based recommendations on optimal selection and dosing of antiretroviral agents for this population.
Lai
Andrew R
AR
Brown Medical School, Providence, Rhode Island, USA.
Tashima
Karen T
KT
Taylor
Lynn E
LE
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects; D016174:Hepacivirus / Q000187:drug effects; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors